血畅宁的抗高血压及靶器官保护效应的机制研究
|
摘要
目的：
高血压是危害人类生命的主要疾病之一,其治疗的最终目标是有效保护靶器官,降低病死率和病残率。传统的西药降压药,降压虽较快捷,但可出现诸多方面的不良反应,在靶器官保护方面的作用未尽人意。中药降压具有多途径、多环节、多靶点的特点,且价格相对较低,在治疗上有着少或无毒副作用的优势,因此如果能够开发出一种既可以降压又对靶器官具有一定保护作用的中成药,那么对于促进中药现代化和促进高血压病的临床康复将具有重要意义。
本课题拟在以往研究的基础上,对根据导师的临床验方“调肝肾、祛痰瘀”组方所开发成的“血畅宁无糖颗粒”进行药效学研究,从心室重构、血管重塑、血管内皮功能等不同层面了解其在治疗高血压病时的作用机制,从而深化对中医治疗高血压病病机的认识,为临床防治高血压病提供新的治疗途径。
方法：
1.血畅宁无糖颗粒：
熟地25g、龟版30g、丹参15g、瓜萎12g、田七5g、钩藤12g。以上生药材经过再次干燥,按处方比例(其中龟板打碎、先煎30min,钩藤后下煎煮5min)混匀,常温下加入蒸馏水浸泡过夜,回流提取,将过滤后的滤出液混合并浓缩,制成浸膏(含生药1g/m1),冷藏备用。
2.实验动物及分组
实验采用两种模型,即自发性高血压大鼠(SHR)模型和自制的“两肾一夹”肾性高血压大鼠(RHR)模型。
(1)RHR按随机数字表法分成5组：
假手术组、模型组、血畅宁高剂量组、血畅宁低剂量组、氯沙坦组,每组10只。
(2)SHR按随机数字表法分成4组：
模型组、血畅宁高剂量组、血畅宁低剂量组、氯沙坦组,每组10只；另外,加设对照组：由普通SD大鼠组成,10只。
3.给药及喂养方式
(1)RHR造模第4周末起,各组大鼠灌胃给药,1次/天。药物灌服的剂量根据临床等效剂量,血畅宁高剂量组为20g生药/kg/d,血畅宁低剂量组为l0g生药/kg/d,氯沙坦组为30mmg/kg/d,给药体积均为1ml/100g。假手术组和模型组均给予1ml/100g的蒸馏水灌胃,每日上午给药一次,持续5周。在实验期间,各组大鼠均以标准饲料喂养,自由饮水。
(2)SHR组于SHR第10周时开始灌胃给药,给药及喂养方式同RHR相应组别的方式,其中对照组同假手术组。
4.研究内容
包括五个部分：①肾性高血压大鼠模型的改良与评价；②血畅宁对两种模型大鼠的血压以及血清NO和AngⅡ含量的影响；③血畅宁对两种模型大鼠心、肾、主动脉等靶器官形态学方面的影响：光镜下观察心、主动脉和肾脏的结构,电镜下观察主动脉和肾脏的超微结构,并测量左室重量和动脉管壁中膜厚度；④免疫组织化学法及RT-PCR法检测血畅宁对两种模型大鼠动脉组织中bFGF.OPN含量及bFGFmRNA、OPNmRNA表达的影响；⑤免疫组织化学法及RT-PCR法检测血畅宁对两种模型大鼠心肌组织中ACE2的含量及AT1RmRNA、 AT2RmRNA、 ACE2mRNA表达的影响。
结果：
1.对SD大鼠造模后,RHR模型组与假手术组比较,模型组在造模后3天收缩压开始升高,7天后血压急剧上升,14天高血压已初步形成,具有显著性差异(P<0.05)。
2.在RHR模型中,治疗5周末,血畅宁高剂量组与氯沙坦组降压效果相当,均优于低剂量组,而在其他各个时间点氯沙坦组血压均比血畅宁高剂量组低。另外,在降低血清AngⅡ含量方面,血畅宁高剂量组优于低剂量组,而氯沙坦组能增高血清AngⅡ含量。在增高血清NO含量方面,血畅宁高剂量组和氯沙坦组相当,均优于低剂量组；在SHR模型中,治疗5周末,氯沙坦组降压效果最好,血畅宁高剂量组降压效果优于低剂量组,在其他各个时间点氯沙坦组血压均比血畅宁高剂量组低。在降低血清AngⅡ含量方面,血畅宁高剂量组优于低剂量组和氯沙坦组。在增高血清NO含量方面,血畅宁高剂量组作用显著,优于低剂量组和氯沙坦组。
3.两种模型中,在降低LVMI、 MT和VFC方面以及对心和主动脉的形态学保护方面的结果一致,血畅宁高剂量组和氯沙坦组效果相当,均优于低剂量组；而在肾脏保护方面,血畅宁高剂量组和低剂量组均有一定的保护效应,而氯沙坦组的肾脏保护效应较差。
4.两种模型中,在降低动脉组织中bFGF、 OPN含量以及bFGFmRNA和OPNmRNA表达方面结果一致,血畅宁高剂量组均优于血畅宁低剂量组和氯沙坦组,而氯沙坦组作用不稳定,有时与血畅宁高剂量组效果相当,有时又与低剂量组效果相当。
5.在增加ACE2含量和AT2R mRNA方面,两种模型的血畅宁高剂量组和氯沙坦组的作用相当,均优于低剂量组,而且治疗效果接近正常对照组；而在降低AT1R mRNA方面氯沙坦组优于血畅宁高剂量组和低剂量组；同时,在ACE2mRNA的表达方面两种模型的结果不一致,在RHR模型中,血畅宁高剂量组和氯沙坦组均可以增加心肌组织中ACE2mRNA的表达,但氯沙坦组的效果更好；在SHR模型中,血畅宁高剂量组可以明显增加心肌组织中ACE2mRNA的表达,而氯沙坦组的效果与血畅宁低剂量组的效果相当,与血畅宁高剂量组比较效果较差。
结论：
1.血畅宁具有明显的降低RHR和SHR血压的作用,但降压较为缓慢,在治疗过程中,动物血压呈现出持续缓慢下降的趋势,虽然降压效果不及氯沙坦迅速,但却显示出了中药降压缓慢平稳,持续降压的优势；
2.血畅宁能够降低RHR和SHR血清AngⅡ含量,同时提高RHR和SHR的血清NO含量,从而改善血管内皮功能；
3.血畅宁可以降低RHR和SHR心肌的LVMI、增加心肌组织中ACE2的含量和ACE2mRNA、 AT2R mRNA的表达,同时还可以降低AT1R mRNA的表达。形态学观察显示血畅宁能显著改善两种模型的主要靶器官心的形态学表现,说明血畅宁有比较明显的改善心室重构的作用,从而抑制了心肌这一靶器官的损伤；
4.血畅宁能够明显降低RHR和SHR主动脉管壁的MT、VFC,降低主动脉组织中bFGF、 OPN的含量以及bFGF mRNA、 OPN mRNA的表达,同时还能够显著改善两种模型的主要靶器官主动脉的形态学表现,说明血畅宁有比较明显的改善动脉血管重塑的作用,从而抑制了主动脉这一靶器官的损伤；
5.血畅宁能够显著改善两种模型的主要靶器官肾脏的形态学表现,从而抑制了大鼠肾脏这一靶器官的损伤。
6.从整体来讲,高剂量血畅宁优于低剂量血畅宁的效果,而且在靶器官保护方面血畅宁效果优于氯沙坦。
Objective
Hypertension is one of the major diseases that endanger human life. The ultimate goal of the treatment is protecting the target organs effectively and reducing the mortality rate and disability rate. Although the efficiency of antihypertensive by Western medicine is fast, there may be many adverse reactions. Moreover, the effect of protecting the target organs by Western medicine is not good. Traditional Chinese medicine (TCM) has characteristics of multi-channel, multi-link and multi-target in treating hypertension and its price is relatively low. In addition, it has little or no adverse reaction. Therefore, the development of proprietary Chinese medicines is of great significance in developing TCM resources and promoting modernization of TCM, especially for the pharmacological research on the active ingredients and mechanism of action.
The primary purpose of this paper is to do a pharmacological research on the Xuechangning sugar free granule based on previous studies. Xuechangning sugar free granule is a new proprietary Chinese medicine that has been developed according to my instructor's clinical prescription named "regulating the function of liver and kidney while removing phlegm and blood stasis". We discuss its Anti-hypertension mechanism from different aspects such as left ventricular remodeling, vascular remodeling and vascular endothelial function, to provide some new ideas in the prevention and treatment of hypertension in clinical practices.
Methods
1. Xuechangning sugar free granule
Radix rehmanniae preparata25g、carapax et plastrum testudins3g、 radix salviae miltiorrhizae15g、 fructus trichosanthis12g、 radix notoginseng5g、 ramulus uncariae cum uncis12g. Raw-material medicine mixed according to recipe portion after a second dry(Break carapax et plastrum testudins into pieces、 fore-decoct30min, and ramulus uncariae cum uncis post-decoct for5min). Add distilled water to soak overnight at air temperature, reflux extraction. Then mixed and concentrated all filtrate, to prepare the extract (containing raw medicine1g per ml), refrigerated ready to use.
2. The animals and groups
The animals used in this experiment are two kinds of rat models:the spontaneously hypertensive rats (SHR) model and "two kidney-one clip" renal hypertensive rats (RHR) model.
(1) RHR are divided into five groups according to the random number table:
Sham operation group, Model group, High-dosage of Xuechangnin group, Low-dosage of Xuechangnin group, Losartan group (n=10).
(2) SHR are divided into four groups according to the random number table:
Model group, High-dosage of Xuechangnin group, Low-dosage of Xuechangnin group, Losartan group (n=10). In addition, there is a control group of10normal SD rats.
3. Administration method
(1) The model rats started administration from the first five weeks after model establishment. The dose of medicine was clinical equivalent dose. High-dosage of Xuechangnin group was supplied with20g raw medicine/kg/d; Low-dosage of Xuechangnin group was supplied with lOg raw medicine/kg/d; losartan group was supplied with30mg/kg/d, administration volumes were all1ml/100g. The sham operation group and model group were both supplied with1ml/100g distilled water. Administered once AM per day for five continuous weeks. During the experiment, the rats in each group were supplied with standard feed and with free access to water.
(2) SHR was administrated at the tenth week. The way of delivery and feeding was the same as the corresponding groups of RHR, and the control group was same with the sham group.
4. Research contents
The research includes five parts:①The improvement and evaluation in method of renal hypertensive model rats;②The effects of Xuechangning on blood pressure and the contents of NO and AngⅡ in serum of two model rats;③The effects of Xuechangning on the morphology in target organs of two model rats, such as heart, kidney and aorta. We observed morphological changes of the heart, aorta and kidney by light microscope and observed the ultrastructure of the aorta and kidney by electron microscopy. Meanwhile, we measured the left ventricular mass and artery intima-media wall thickness;④The protein production of bFGF and OPN in the aortic tissue of two model rats were detected by immunohistochemical, while the mRNA expression of bFGF and OPN were detected by RT-PCR;⑤The protein production of ACE2in the myocardial tissue of two model rats were detected by immunohistochemical, while the mRNA expression of AT1R AT2R and ACE2were detected by RT-PCR.
Results
1. Compared with sham operation group, systolic blood pressure of model group began to increase on the3rd day after building the models, and then significantly increased on the7th day. And hypertension has been initially formed on the14th day; there were significant differences compared with sham operation group (P<0.05).
2. In the RHR model, the antihypertensive effect on high-dosage of Xuechangnin group was equal to the effect of the losartan group after fifth week's treatment; they are both better than the low-dosage of Xuechangnin group. Meanwhile, the blood pressure of losartan group is lower than high-dosage of Xuechangnin group in each of the other time points. In addition high-dosage of Xuechangnin group is better than the low-dosage of Xuechangnin group in reducing serum AngⅡ content. Meanwhile, losartan group increased serum AngⅡ content. High-dosage of Xuechangnin group was equal to losartan group in increasing serum NO content; they are both better than the low-dosage of Xuechangnin group; In the SHR model, the antihypertensive effect on high-dosage of Xuechangnin group is equal to losartan group after fifth weeks treatment, are both better than the low-dosage of Xuechangnin group. Meanwhile, the blood pressure of losartan group is lower than high-dosage of Xuechangnin group in each of the other time points. High-dosage of Xuechangnin group is best in reducing serum AngⅡcontent. In addition, high-dosage of Xuechangnin group has a significant effect on increasing serum NO, bettei than low-dosage of Xuechangnin group and losartan group.
3. We obtained consistent results in the two models:the role of reducing LVMI, MT, and VFC and inhibiting morphological change of the heart and aorta are considerable in high-dosage of Xuechangnin group and losartan group, and both better than the low-dosage of Xuechangnin group; In addition, high-dosage of Xuechangnin group and low-dosage of Xuechangnin group had a certain protective effect on the kidney, While losartan group had a relatively poor protective effect on the kidney.
4. The result suggests that RHR groups are consistent with that of SHR groups in reducing the protein production of bFGF and OPN and their mRNA expression in the aortic tissue. We found that high-dosage of Xuechangnin group is superior to low-dosage of Xuechangnin group and losartan group. While the role of the losartan group is unstable, sometimes equal to the high-dosage of Xuechangnin group, sometimes equal to the low-dosage of Xuechangnin group.
5. The result shows that RHR groups are equal to that of SHR groups in increasing protein production of ACE2and AT2RmRNA expression in the myocardial tissue. We found that the effects are considerable in high-dosage of Xuechangnin group and losartan group, they are both better than low-dosage of Xuechangnin group and close to the normal control group; while the role of reducing ATlRmRNA expression in Losartan group is better than high-dosage of Xuechangnin group and low-dosage of Xuechangnin group; Besides, the results show that RHR groups are equal to that of SHR groups in ACE2mRNA expression. In the RHR model, we found that high-dosage of Xuechangnin group and losartan group both can increase ACE2mRNA expression of the myocardial tissue, but the losartan group is better; in the SHR model, we found that high-dosage of Xuechangnin group can increase ACE2mRNA expression of the myocardial tissue significantly, and is better than the losartan group and the low-dosage of Xuechangnin group, while the latter two effects are relatively poor.
Conclusion
1. Xuechangning has a significant effect on reducing blood pressure of the two models. The blood pressure of rats showed a slow but continued decreasing tendency in the whole period of experiment. Although the effect of antihypertensive is not as good as losartan, it shows advantages of TCM in reducing the blood pressure slowly, steadily and continuously;
2. Xuechangning can reduce the contents of Angll in serum of two model rats, while increase the contents of NO in serum of two model rats. So it can improve the endothelial function;
3. Xuechangning can reduce LVMI, increase protein production of ACE2and expression of ACE2mRNA and AT2RmRNA in the myocardial tissue, while reducing the expression of ATlRmRNA. Morphological observation of myocardial tissue showed that Xuechangning can significantly improve morphological features of the heart of the two models. It is illustrated that Xuechangning can improved ventricular remodeling significantly, thus inhibiting the damage of this target organ;
4. Xuechangning can significantly reduce Mt and VFC in thoracic aorta wall of RHR and SHR, reduce the protein production of bFGF and OPN and their mRNA expression in the aortic tissue, and significantly improve morphological manifestations of the aorta. It is illustrated that Xuechangning can improved arterial vascular remodeling obviously, thus inhibiting the damage of this target organ;
5. Xuechangning can significantly improve the kidney morphologic features of the two models, thus inhibiting the damage of this target organ;
6. Generally speaking, we obtained consistent results in the two models: the high-dosage of Xuechangnin group excels the low one. The effect on protecting the target organ of Xuechangning is superior to that of losartan.
高血压是危害人类生命的主要疾病之一,其治疗的最终目标是有效保护靶器官,降低病死率和病残率。传统的西药降压药,降压虽较快捷,但可出现诸多方面的不良反应,在靶器官保护方面的作用未尽人意。中药降压具有多途径、多环节、多靶点的特点,且价格相对较低,在治疗上有着少或无毒副作用的优势,因此如果能够开发出一种既可以降压又对靶器官具有一定保护作用的中成药,那么对于促进中药现代化和促进高血压病的临床康复将具有重要意义。
本课题拟在以往研究的基础上,对根据导师的临床验方“调肝肾、祛痰瘀”组方所开发成的“血畅宁无糖颗粒”进行药效学研究,从心室重构、血管重塑、血管内皮功能等不同层面了解其在治疗高血压病时的作用机制,从而深化对中医治疗高血压病病机的认识,为临床防治高血压病提供新的治疗途径。
方法：
1.血畅宁无糖颗粒：
熟地25g、龟版30g、丹参15g、瓜萎12g、田七5g、钩藤12g。以上生药材经过再次干燥,按处方比例(其中龟板打碎、先煎30min,钩藤后下煎煮5min)混匀,常温下加入蒸馏水浸泡过夜,回流提取,将过滤后的滤出液混合并浓缩,制成浸膏(含生药1g/m1),冷藏备用。
2.实验动物及分组
实验采用两种模型,即自发性高血压大鼠(SHR)模型和自制的“两肾一夹”肾性高血压大鼠(RHR)模型。
(1)RHR按随机数字表法分成5组：
假手术组、模型组、血畅宁高剂量组、血畅宁低剂量组、氯沙坦组,每组10只。
(2)SHR按随机数字表法分成4组：
模型组、血畅宁高剂量组、血畅宁低剂量组、氯沙坦组,每组10只；另外,加设对照组：由普通SD大鼠组成,10只。
3.给药及喂养方式
(1)RHR造模第4周末起,各组大鼠灌胃给药,1次/天。药物灌服的剂量根据临床等效剂量,血畅宁高剂量组为20g生药/kg/d,血畅宁低剂量组为l0g生药/kg/d,氯沙坦组为30mmg/kg/d,给药体积均为1ml/100g。假手术组和模型组均给予1ml/100g的蒸馏水灌胃,每日上午给药一次,持续5周。在实验期间,各组大鼠均以标准饲料喂养,自由饮水。
(2)SHR组于SHR第10周时开始灌胃给药,给药及喂养方式同RHR相应组别的方式,其中对照组同假手术组。
4.研究内容
包括五个部分：①肾性高血压大鼠模型的改良与评价；②血畅宁对两种模型大鼠的血压以及血清NO和AngⅡ含量的影响；③血畅宁对两种模型大鼠心、肾、主动脉等靶器官形态学方面的影响：光镜下观察心、主动脉和肾脏的结构,电镜下观察主动脉和肾脏的超微结构,并测量左室重量和动脉管壁中膜厚度；④免疫组织化学法及RT-PCR法检测血畅宁对两种模型大鼠动脉组织中bFGF.OPN含量及bFGFmRNA、OPNmRNA表达的影响；⑤免疫组织化学法及RT-PCR法检测血畅宁对两种模型大鼠心肌组织中ACE2的含量及AT1RmRNA、 AT2RmRNA、 ACE2mRNA表达的影响。
结果：
1.对SD大鼠造模后,RHR模型组与假手术组比较,模型组在造模后3天收缩压开始升高,7天后血压急剧上升,14天高血压已初步形成,具有显著性差异(P<0.05)。
2.在RHR模型中,治疗5周末,血畅宁高剂量组与氯沙坦组降压效果相当,均优于低剂量组,而在其他各个时间点氯沙坦组血压均比血畅宁高剂量组低。另外,在降低血清AngⅡ含量方面,血畅宁高剂量组优于低剂量组,而氯沙坦组能增高血清AngⅡ含量。在增高血清NO含量方面,血畅宁高剂量组和氯沙坦组相当,均优于低剂量组；在SHR模型中,治疗5周末,氯沙坦组降压效果最好,血畅宁高剂量组降压效果优于低剂量组,在其他各个时间点氯沙坦组血压均比血畅宁高剂量组低。在降低血清AngⅡ含量方面,血畅宁高剂量组优于低剂量组和氯沙坦组。在增高血清NO含量方面,血畅宁高剂量组作用显著,优于低剂量组和氯沙坦组。
3.两种模型中,在降低LVMI、 MT和VFC方面以及对心和主动脉的形态学保护方面的结果一致,血畅宁高剂量组和氯沙坦组效果相当,均优于低剂量组；而在肾脏保护方面,血畅宁高剂量组和低剂量组均有一定的保护效应,而氯沙坦组的肾脏保护效应较差。
4.两种模型中,在降低动脉组织中bFGF、 OPN含量以及bFGFmRNA和OPNmRNA表达方面结果一致,血畅宁高剂量组均优于血畅宁低剂量组和氯沙坦组,而氯沙坦组作用不稳定,有时与血畅宁高剂量组效果相当,有时又与低剂量组效果相当。
5.在增加ACE2含量和AT2R mRNA方面,两种模型的血畅宁高剂量组和氯沙坦组的作用相当,均优于低剂量组,而且治疗效果接近正常对照组；而在降低AT1R mRNA方面氯沙坦组优于血畅宁高剂量组和低剂量组；同时,在ACE2mRNA的表达方面两种模型的结果不一致,在RHR模型中,血畅宁高剂量组和氯沙坦组均可以增加心肌组织中ACE2mRNA的表达,但氯沙坦组的效果更好；在SHR模型中,血畅宁高剂量组可以明显增加心肌组织中ACE2mRNA的表达,而氯沙坦组的效果与血畅宁低剂量组的效果相当,与血畅宁高剂量组比较效果较差。
结论：
1.血畅宁具有明显的降低RHR和SHR血压的作用,但降压较为缓慢,在治疗过程中,动物血压呈现出持续缓慢下降的趋势,虽然降压效果不及氯沙坦迅速,但却显示出了中药降压缓慢平稳,持续降压的优势；
2.血畅宁能够降低RHR和SHR血清AngⅡ含量,同时提高RHR和SHR的血清NO含量,从而改善血管内皮功能；
3.血畅宁可以降低RHR和SHR心肌的LVMI、增加心肌组织中ACE2的含量和ACE2mRNA、 AT2R mRNA的表达,同时还可以降低AT1R mRNA的表达。形态学观察显示血畅宁能显著改善两种模型的主要靶器官心的形态学表现,说明血畅宁有比较明显的改善心室重构的作用,从而抑制了心肌这一靶器官的损伤；
4.血畅宁能够明显降低RHR和SHR主动脉管壁的MT、VFC,降低主动脉组织中bFGF、 OPN的含量以及bFGF mRNA、 OPN mRNA的表达,同时还能够显著改善两种模型的主要靶器官主动脉的形态学表现,说明血畅宁有比较明显的改善动脉血管重塑的作用,从而抑制了主动脉这一靶器官的损伤；
5.血畅宁能够显著改善两种模型的主要靶器官肾脏的形态学表现,从而抑制了大鼠肾脏这一靶器官的损伤。
6.从整体来讲,高剂量血畅宁优于低剂量血畅宁的效果,而且在靶器官保护方面血畅宁效果优于氯沙坦。
Objective
Hypertension is one of the major diseases that endanger human life. The ultimate goal of the treatment is protecting the target organs effectively and reducing the mortality rate and disability rate. Although the efficiency of antihypertensive by Western medicine is fast, there may be many adverse reactions. Moreover, the effect of protecting the target organs by Western medicine is not good. Traditional Chinese medicine (TCM) has characteristics of multi-channel, multi-link and multi-target in treating hypertension and its price is relatively low. In addition, it has little or no adverse reaction. Therefore, the development of proprietary Chinese medicines is of great significance in developing TCM resources and promoting modernization of TCM, especially for the pharmacological research on the active ingredients and mechanism of action.
The primary purpose of this paper is to do a pharmacological research on the Xuechangning sugar free granule based on previous studies. Xuechangning sugar free granule is a new proprietary Chinese medicine that has been developed according to my instructor's clinical prescription named "regulating the function of liver and kidney while removing phlegm and blood stasis". We discuss its Anti-hypertension mechanism from different aspects such as left ventricular remodeling, vascular remodeling and vascular endothelial function, to provide some new ideas in the prevention and treatment of hypertension in clinical practices.
Methods
1. Xuechangning sugar free granule
Radix rehmanniae preparata25g、carapax et plastrum testudins3g、 radix salviae miltiorrhizae15g、 fructus trichosanthis12g、 radix notoginseng5g、 ramulus uncariae cum uncis12g. Raw-material medicine mixed according to recipe portion after a second dry(Break carapax et plastrum testudins into pieces、 fore-decoct30min, and ramulus uncariae cum uncis post-decoct for5min). Add distilled water to soak overnight at air temperature, reflux extraction. Then mixed and concentrated all filtrate, to prepare the extract (containing raw medicine1g per ml), refrigerated ready to use.
2. The animals and groups
The animals used in this experiment are two kinds of rat models:the spontaneously hypertensive rats (SHR) model and "two kidney-one clip" renal hypertensive rats (RHR) model.
(1) RHR are divided into five groups according to the random number table:
Sham operation group, Model group, High-dosage of Xuechangnin group, Low-dosage of Xuechangnin group, Losartan group (n=10).
(2) SHR are divided into four groups according to the random number table:
Model group, High-dosage of Xuechangnin group, Low-dosage of Xuechangnin group, Losartan group (n=10). In addition, there is a control group of10normal SD rats.
3. Administration method
(1) The model rats started administration from the first five weeks after model establishment. The dose of medicine was clinical equivalent dose. High-dosage of Xuechangnin group was supplied with20g raw medicine/kg/d; Low-dosage of Xuechangnin group was supplied with lOg raw medicine/kg/d; losartan group was supplied with30mg/kg/d, administration volumes were all1ml/100g. The sham operation group and model group were both supplied with1ml/100g distilled water. Administered once AM per day for five continuous weeks. During the experiment, the rats in each group were supplied with standard feed and with free access to water.
(2) SHR was administrated at the tenth week. The way of delivery and feeding was the same as the corresponding groups of RHR, and the control group was same with the sham group.
4. Research contents
The research includes five parts:①The improvement and evaluation in method of renal hypertensive model rats;②The effects of Xuechangning on blood pressure and the contents of NO and AngⅡ in serum of two model rats;③The effects of Xuechangning on the morphology in target organs of two model rats, such as heart, kidney and aorta. We observed morphological changes of the heart, aorta and kidney by light microscope and observed the ultrastructure of the aorta and kidney by electron microscopy. Meanwhile, we measured the left ventricular mass and artery intima-media wall thickness;④The protein production of bFGF and OPN in the aortic tissue of two model rats were detected by immunohistochemical, while the mRNA expression of bFGF and OPN were detected by RT-PCR;⑤The protein production of ACE2in the myocardial tissue of two model rats were detected by immunohistochemical, while the mRNA expression of AT1R AT2R and ACE2were detected by RT-PCR.
Results
1. Compared with sham operation group, systolic blood pressure of model group began to increase on the3rd day after building the models, and then significantly increased on the7th day. And hypertension has been initially formed on the14th day; there were significant differences compared with sham operation group (P<0.05).
2. In the RHR model, the antihypertensive effect on high-dosage of Xuechangnin group was equal to the effect of the losartan group after fifth week's treatment; they are both better than the low-dosage of Xuechangnin group. Meanwhile, the blood pressure of losartan group is lower than high-dosage of Xuechangnin group in each of the other time points. In addition high-dosage of Xuechangnin group is better than the low-dosage of Xuechangnin group in reducing serum AngⅡ content. Meanwhile, losartan group increased serum AngⅡ content. High-dosage of Xuechangnin group was equal to losartan group in increasing serum NO content; they are both better than the low-dosage of Xuechangnin group; In the SHR model, the antihypertensive effect on high-dosage of Xuechangnin group is equal to losartan group after fifth weeks treatment, are both better than the low-dosage of Xuechangnin group. Meanwhile, the blood pressure of losartan group is lower than high-dosage of Xuechangnin group in each of the other time points. High-dosage of Xuechangnin group is best in reducing serum AngⅡcontent. In addition, high-dosage of Xuechangnin group has a significant effect on increasing serum NO, bettei than low-dosage of Xuechangnin group and losartan group.
3. We obtained consistent results in the two models:the role of reducing LVMI, MT, and VFC and inhibiting morphological change of the heart and aorta are considerable in high-dosage of Xuechangnin group and losartan group, and both better than the low-dosage of Xuechangnin group; In addition, high-dosage of Xuechangnin group and low-dosage of Xuechangnin group had a certain protective effect on the kidney, While losartan group had a relatively poor protective effect on the kidney.
4. The result suggests that RHR groups are consistent with that of SHR groups in reducing the protein production of bFGF and OPN and their mRNA expression in the aortic tissue. We found that high-dosage of Xuechangnin group is superior to low-dosage of Xuechangnin group and losartan group. While the role of the losartan group is unstable, sometimes equal to the high-dosage of Xuechangnin group, sometimes equal to the low-dosage of Xuechangnin group.
5. The result shows that RHR groups are equal to that of SHR groups in increasing protein production of ACE2and AT2RmRNA expression in the myocardial tissue. We found that the effects are considerable in high-dosage of Xuechangnin group and losartan group, they are both better than low-dosage of Xuechangnin group and close to the normal control group; while the role of reducing ATlRmRNA expression in Losartan group is better than high-dosage of Xuechangnin group and low-dosage of Xuechangnin group; Besides, the results show that RHR groups are equal to that of SHR groups in ACE2mRNA expression. In the RHR model, we found that high-dosage of Xuechangnin group and losartan group both can increase ACE2mRNA expression of the myocardial tissue, but the losartan group is better; in the SHR model, we found that high-dosage of Xuechangnin group can increase ACE2mRNA expression of the myocardial tissue significantly, and is better than the losartan group and the low-dosage of Xuechangnin group, while the latter two effects are relatively poor.
Conclusion
1. Xuechangning has a significant effect on reducing blood pressure of the two models. The blood pressure of rats showed a slow but continued decreasing tendency in the whole period of experiment. Although the effect of antihypertensive is not as good as losartan, it shows advantages of TCM in reducing the blood pressure slowly, steadily and continuously;
2. Xuechangning can reduce the contents of Angll in serum of two model rats, while increase the contents of NO in serum of two model rats. So it can improve the endothelial function;
3. Xuechangning can reduce LVMI, increase protein production of ACE2and expression of ACE2mRNA and AT2RmRNA in the myocardial tissue, while reducing the expression of ATlRmRNA. Morphological observation of myocardial tissue showed that Xuechangning can significantly improve morphological features of the heart of the two models. It is illustrated that Xuechangning can improved ventricular remodeling significantly, thus inhibiting the damage of this target organ;
4. Xuechangning can significantly reduce Mt and VFC in thoracic aorta wall of RHR and SHR, reduce the protein production of bFGF and OPN and their mRNA expression in the aortic tissue, and significantly improve morphological manifestations of the aorta. It is illustrated that Xuechangning can improved arterial vascular remodeling obviously, thus inhibiting the damage of this target organ;
5. Xuechangning can significantly improve the kidney morphologic features of the two models, thus inhibiting the damage of this target organ;
6. Generally speaking, we obtained consistent results in the two models: the high-dosage of Xuechangnin group excels the low one. The effect on protecting the target organ of Xuechangning is superior to that of losartan.
引文
[1]李剑,史亚飞,严灿等.原发性高血压中医病机及其从痰瘀论治的机理探讨[J].江西中医药,2003,34(245)：11-12.
[2]唐培位.高血压病气虚证中医辩证施治探微.新疆中医药,2011,19(2)：7-8.
[3]刘桂林.高血压病气虚机制浅析[J].山东中医杂志,2003,22(1)：9-10.
[4]邓国琼,邓德强.益气升清法在高血压病中的运用[J].中国中医药信息杂志,2007,14(9)：79.
[5]袁卫红,贺泽龙.高血压病的辨病辨证治疗思路探讨[J].湖南中医药导报,2000,6(5)：10-11.
[6]李青鸟.原发性高血压病病因之我见[J].光明中医,2000,15(1)：8-11.
[7]李雪苓,韩宁林,周大勇等.养阴活血法治疗阴虚阳亢型原发性高血压的临床研究[J].安徽中医学院学报,2007,26(4)：10.
[8]郑林.高血压病的中医研究评析[J].中医药学刊,2003,21(12)：2131.
[9]郭世平,何鲜平,林秀美,等.加味半夏白术天麻汤治疗原发性痰浊中阻型高血压60例[J].陕西中医,2006,27(7)：797-798.
[10]孟庆刚,魏成,帕丽旦,等.试论痰瘀同源[J].山东中医杂志,2006,25(7)：443-445.
[11]徐树楠,刘海丽.高血压病的中医病理学特点探微[J].中国中医基础医学杂志,2003,9(9)：10.
[12]李武明,何玉香,谭元生.复方杜仲降压片治疗高血压病45例分析[J].中医药学,2004,22(2)：33卜332.
[13]韩学杰,朱研,李成卫.原发性高血压病中医病因理论探讨[J].医学研究杂志,2007,36(8)：6.
[14]徐树楠,张再康.从瘀论治高血压病探讨[J].中国中医基础医学杂志,2004,8(10)：38.
[15]靳立民.原发性高血压病的中医病机探讨[J].亚太传统医药,2005,2：40.
[16]韩学杰,沈宁.毒损心络与高血压病[J].中医杂志,2005,46(2)：155-156.
[17]王丹,杨振伟.高血压病基本证型与血瘀的相关性研究[J].江西中医学院学报,2007,19(1)： 54-56.
[18]李成卫.原发性高血压病痰瘀同治整体治疗方案设计[J].中国医药学报,2004,19(10)：626.
[19]于向东,崔军.从络论治高血压的理论探讨[J].中国临床康复,2003,24(7)：3364-3365.
[20]邓中炎,徐志伟,陈群,等.中医基础理论体系现代研究.广州：广东科技出版社,2002,1：7,88,193.
[21]叶任高.内科学.北京：人民卫生出版社,2002,5：258-261.
[22]邓铁涛.邓铁涛医学文集.北京：人民卫生出版社,2001,1：19.
[23]肖梅芳,周端.活血潜阳颗粒对自发性高血压大鼠血浆肾素血管紧张素系统的影响[J].上海中医药杂志,2007,41(7)：59.
[24]牟林茂,李安源,司国民,等.平肾通络降压颗粒对自发性高血压大鼠血压及肾素-血管紧张素系统的影响[J].中国中医药信息杂志,2008,15(12)：36.
[25]靳宏光,黄永生.夏膝口服液对自发性高血压大鼠肾素血管紧张素Ⅱ水平的影响[J].中华中医药学刊,2007,25(5)：1019-1021.
[26]尚明月.地黄降压汤对肾性高血压大鼠血压及血浆血管紧张素Ⅱ、醛固酮影响的实验研究.吉林大学学报,2007,1：1.
[27]李建平,严灿,邓中炎,等.活血祛痰方药预防自发性高血压大鼠心肌纤维化实验研究[J].中医杂志,2000,41(5)：301-302.
[28]粱颖瑜,潘毅,徐志伟,等.“调肝肾、祛痰瘀”治法早期干预自发性高血压大鼠子鼠血压及VSMC钙离子浓度的影响[J].医学信息,2003,16(7)：398-400.
[29]许东元,金东洙,金范学.三黄泻心汤水提取液对大鼠离体胸主动脉环的舒张作用及机制[J].四川中医,2008,26(10)：11.
[30]郑非,李树青.通心络对自发性高血压大鼠血管内皮功能的影响[J].中西医结合心血管病杂志,2009,7(2)：179.
[31]葛华,赵英莉,王璇,等.通心络对高血压大鼠血管内皮功能保护作用的研究.首届国际络病学大会论文集.北京.中国.2005.第1卷.
[32]刘真,于慧卿,魏运湘,等.夏枯草汤治疗高血压病及对血管内皮功能的影响[J].陕西中医,2006,27(2)：162.
[33]武文辉,吉中强,纪文岩.新血府逐瘀汤对高血压大鼠内皮功能及血栓前状态影响[J].中西医结合心血管病杂志,2007,5(11)：1084.
[34]李辉,徐贵成,刘坤,等.息化饮2号对高血压模型大鼠的降压实验及活血化瘀作用研究.北京中医药大学学报,2003,26(4)：47.
[35]陈利群.健脾化痰活血祛瘀法对痰瘀互阻型原发性高血压病患者血脂和血液流变学的影响.河北中医,2005,27(2)：93-95.
[36]金雪元.高血压病与胰岛素抵抗的研究进展.中国优秀硕士学位论文全文数据库,2008,(1)：1.
[37]杨晔,王志国,王浩,等.金芪降糖片对胰岛素抵抗和高血压的影响.天津医药,2005,33(5)：298-230.
[38]司晓晨,播杨,程海波等.胰敏胶囊阻止果糖诱导的胰岛素抵抗大鼠高血压的发生研究.中医药学刊,2004,22(2)：250-252.
[39]徐京育,苏润泽,张良.复方槐花降压冲剂治疗胰岛素抵抗性高血压[J].中西医结合心脑 血管病杂志,2005,3(6)：489-490.
[40]熊一力,王嘉陵,钱家庆.莲心碱对内皮素促血管平滑肌细胞增殖及原癌基因表达的影响[J].中国现代医学杂志,1999,9(2)：1-3.
[41]邓杰,熊玮,郑智.丹参对自发性高血压大鼠心肌细胞凋亡及基因蛋白表达的影响[J].江西医药,2003,38(5)：322-324.
[42]张茗,李敬孝,益心胶囊对肾性高血压大鼠左室肥厚及c-fos基因表达的影响[J].中医药信息,2008,25(2)：57-58.
[43]Suzanne Oparil Michael A, Weber. Hypertension[M]. 北京：北京大学医学出版社,2008: 265.
[44]Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocrine Reviews,2003,24: 261-271.
[45]Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensinⅠto angiotensin 1-9. Circ Res.2000,87(5): E1-E9.
[46]DonoghueM, HsiehF, Baronas E, et al. A novel angiotensin converting enzyme related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Cir Res,2000,87: el-e9.
[47]Gallagher PE, Chappell MC, Bernish WB, et al. ACE2 expression in brain:angiotensin II down-regulates ACE2 in astrocytes. Hypertension,2003,42:389.
[48]Giner V, Poch E, Bragulat E, el al. Renin-angiotensin system genetic polymorphisms and salt sensitivity in essential hypertension, Hypertension,2000,35:512-517.
[49]Tamaki S, Nakamura Y, Tsujita Y, et al. Polymorphism of the angiotensin converting enzyme gene and blood Pressure in a Japanese general population (the Shigaraki Study), Hypertens Res,2002,25:843-848.
[50]Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase, J Biol Chem,2002,277:4838-4843.
[51]Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function, Nature, vol.2002,417:822-828.
[52]Gurley SB, Allred A, Le TH, et al. Altered blood Pressure responses and normal cardiac phenotype in ACE2-null mice, J Clin Invest,2006,116:2218-2225.
[53]Tikellis C, CooPer ME, Bialkowski K, et al. Developmental expression of ACE2 in the SHR kidney:a role in hypertension? Kidney Int,2006,70:34-41.
[54]Rentzseh B, TOdiras M, Iliescu R, et al. Transgenic angiotensin-converting enzyme 2 over expression in vessels of SHR SP rats reduces blood pressure and improves endothelial function, Hypertension,2008,52:967-973.
[56]王向宇,吴可贵,张更等.自发性高血压大鼠高血压形成前期血管平滑肌细胞增殖和肾素-血管紧张素系统的关系.中华心血管病杂志,1997,25(3)：225-228.
[57]Kiliszek M, Burzynska B, Styczynski G, et al. A1166C polymorphism of the angiotensin ATI receptor(ATl R)gene alters endothelial response to statin treatment[J]. Clin Chem Lab Med,2007,45(7):839-842.
[58]Rehmn A, Rasool AH, Naing L, et al. Influence of the Angiotensin Ⅱtpye 1 receptor genel166A>C polymorphismon BP nadaortic pulse wave velocity among MaLays[J]. Ann Hum Genet,2007,71 (Pt 1):86-95.
[59]Schulman IH, Raij L. The angiotensin II type 2 receptor:what is its clinical significance[J]. Curr Hypertens Rep.2008,10(3):188-193.
[60]Widdop RE, Vinh A, HenriON, et al. Vascular angiotensin AT2 receptors in hypertension and ageing[J]. Clin Exp Pharmacol Physiol,2008,35(9):386-390.
[61]Yayama K, Horii M. Hiyoshi H, et al. Up-regulation of angiotensinIItype 2 receptor in rat thoracic by aorta by pressure overload[J]. J Pharmacol Exp Ther,2004,308(2): 736-743.
[62]Cines DB, Pollak ES, Buck C, Loscalzo J, Zimmerman GA, McEver RP, et aL. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood,1998,91: 3527-3561.
[63]Rekhviashvili A, Abashidze R. The relationship between endothelial dysfunction and 24-hour blood pressure rhythm in patients with arterial hypertension[J]. Georgian Med News,2008, (155):13-17.
[64]陈维洲.血管内皮细胞舒缩血管物质与心血管疾病[J].生物科学信息,1991,3：25-23.
[65]Mccarty MF. UP-regulation of endothelial nitric oxide activity as a central strategy prevention of ischemie stroke-just say NO to stroke[J]. Med HyPotheses,2000,55(5): 386-403.
[66]Yang Z, Venardos K, Jones E, et al. Identification of a novel polymorphism in the 3'UTR of the L-arginine transporter gene SLC7AI Contribution to hypertension and endothelial dysfunction[J]. Circulation,2007,115:1269-1274.
[67]韩若凌.一氧化氮、内皮素与原发性高血压的关系[J].河北医药,1998,20(1)：16-19.
[68]Cai H, Davis ME, Drummond GR Harrison DG Induction of endothelial NO synthase by hydrogen peroxide via a Ca2+/calmodulin-dependent protein kinas alias kinase 2-dependent pathway. Artcrioscler Thromb Vase Biol,2001,21:1571-1576.
[69]Rubanyi GM. The role of endthelium in cardiovascular homeostasis and diseases [J].J Cardiovasc Pharmacol,1993,22(suppl 4):S1-S14.
[70]Unger T, Ganten D, Lang RE. Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? studies with the two different compounds. HOE-498 and MK-421 in spontaneously hypertensive rats [J].J Cardiovase Pharmacol,1994,6:872-880.
[71]丛洪良,黄体钢,周丽娟,等.NO,AngⅡ对大鼠主动脉内皮细胞功能及形态学影响的实验研究.高血压杂志,2007(4)：374-375.
[72]Franco C, Ho B, Mulholland D, et al. Doxycycline alters vascular smooth muscle cell adhesion, migration, and reorganization of fibrillar collagen matrices[J].Am J Pathol. 2006,168(5):1697-709.
[73]Reape T J. IGF-1 increases b-FGF-induced mitogenesis and up regulates FGFR-1 in rabbits VSMC[J]. Am j Physiol,1996,270(4):1141.
[74]Peoples GE, Blotnick S, Takahashi K, et al. T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor:a potential pathologic role. Proc Natl Acad Sci USA,1995:92(14):6547-6551.
[75]Eckenstein FP. Fibroblast growth factors in the nervous system. Neuro,1994, 5(18):467-480.
[76]Cuevas P, Carceller F, ortega S, et al. Hypertensive activity of fibroblast growth factor. Sei USA,1991,254:2108-2109.
[77]王晓红,姜志胜,迪丽努尔,等.碱性成纤维细胞生长因子对兔血管舒张功能及左旋精氨酸／一氧化氮途径的影响[J].中国病理生理杂志,1999,15(3)：245.
[78]Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopentin):an early component of type-1 (cell-mediated)in munity[J]. Science,2000,287(5454):860-4.
[79]Hotte SJ, Winquist EW, Stitt L, et al. Plasma osteopontin associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma[J]. Cancer, 2002,95:506-512.
[80]Giachelli C, Bae N, Lombardi D, et al. Molecular cloning and characterization of 287, a rat mRNA which distinguishes smooth muscle cell phenotypes in vitro and is identical to osteopontin(secreted phosphoprotein I,2aR). Biochem Biophys Res Commun,1991,177(2): 867-873.
[81]Chaulet H, Desgranges C, Renault MA, et al. Extracellular nucleotides induce arterial smooth muscle cell migration via osteopontin[J]. Circ Res,2001,89(9):772-778.
[82]Panda D, Kundu GC, Lee BI, et al. Potential roles of osteopontin and alphaVbeta3 angioplasty. integrin in the development of coronary artery restenosis after Proc Natl Acad Sci USA.1997,94(17):9308-9813.
[83]Rebsamen MC, Sun J, Norman AW, et al.I alpha,25-dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ Res, 2002,91(1):17-24.
[84]Weintraub AS, Schnapp LM, Lin X, et al. Osteopontin deficiency in rat vascular smooth muscle cells is associated with an inability to adhere to collagen and increased apoptosis [J]. Lab Invest,2000,80(11):1603-1615.
[85]Schlaepfer DD, Jones KC, Hunter T. Multiple Grb2-mediated integrin-stimulated signaling pathways to ERKZ/mitogen-activated protein kinase:summation of bothc-Src-and focal adhesion kinase-initiated tyrosine phosphorylation events. Mol Cell Biol,1998, 18(5):2571-2585.
[86]Renault MA, Jalvy S, Belloc I, et al. AP-1 is involved in UTP-induced osteopontin expression in arterial smooth muscle cells[J]. Circ Res,2003,93(7):674-681.
[87]Lauer MS, Anderson KM, Kannel W, et al. The impact of obesity on left ventriculammss and geometry, the frammgham study. JAMA,2009,226:231.
[88]Yamazaki T, Komuro I, Kudoh S, et al. Angiotensin Ⅱ partly mediates mechaical stressinduce D cardial hypertroph. GRRes,2008,77:258.
[89]Kent T, Hooberk S, Cooper VG. Loadresonses of protein synthesis in adult mammalian myocardium:role of cardiac defor-mation linked to sodium in flux. Cir Res,2008,64: 72.
[90]Cripis TR, Malik M, Faffell TG, et al. Prognostic value of reuced heart rate variability after myocardial infarction:clinical evaluation of a new analysis method. Br Heart J, 2009,65:96.
[90]Smajilovic S. Novel role of the calcium-sensing receptor in blood pressure modulation. Hypertension,2008,52:994-1000.
[91]Shonghnessy KM, Karet. Salt handling and hypertension. Annu Rev Nutr,2006,26: 343-365.
[92]lawes CM, Vander Hooms, Rodrgers A. Global burden of blood pressure related disease. Lancet,2008,371:1513-1518.
[93]Sarafidis AP, Bakris GL. Resistant hypertension:an overview of evaluation and treatment. J Am coll cardiol,2008,52:1749-1757.
[1]戴勇,彭武建,徐卓佳.“两肾一夹”肾性高血压大鼠模型的改进[J].实验动物科学与管理,2006,2(23)：60-62.
[2]曹珊珊,李瑞芳,方伟进,等.肾性高血压大鼠模型制作的改良方法.河南科技大学学报(医学版),2010,3(28)：165-167.
[3]顾德官,顾天华,宋代军,等.试验性高血压大鼠的血压观察.上海第二医学院学报,1985,2：102-104.
[4]Sun ZJ, Zhang ZE. Historic perspectives and recent advances in major animal models of hypertension. Acta Pharmacol Sin,2005,26(3):295-301.
[5]Pravenec M, Zidek V, Landa V, et al. Genetic analysis of cardiovascular risk factor clustering in spontaneous hypertension. Folia Biol(Praha).2000,46(6):233-240.
[6]Mann JF, Phillips.MI, Dietz R, et al. Effects of central and peripheral angiotensin blockade in hypertensive rats. Am J Physiol.1978,234(5):H629-637.
[7]Trippodo NC, Frohlich ED. Similarities of genetic(spontaneous) hypertension. Man and rat. Circ Re,1981,48(3):309-319.
[8]Yagil Y, Yagil C. Genetic models of hypertension in experimental animals. Exp Nephrol, 2001,9(1):1-9.
[9]James 0 Davis, et al. Pathogenesis of chronic renovascular hypertension. Circulation Research,1977,40:399.
[10]傅继华,陈宇飞,张琪.肾性高血压大鼠实验模型制作改进[J].中国药科大学学报,1995,26(6)：383-384.
[11]孙琪,黄荣桂,郑兴中,等.一肾一夹肾血管性高血压动物模型的制作[J].临床军医杂志,2007,35(6)：812-814.
[1]潘毅,蔡三郎,柳琳,调肝肾祛痰瘀复方含药血清对SHR血管平滑肌细胞肾素-血管紧张素系统的影响.中华中医药学刊,2009,27(6)：1135-1139.
[2]潘毅,柳琳,蔡三郎等.调肝肾祛痰瘀复方发病前不同时段给药对SHR血管重构的整体药效学 研究.辽宁中医杂志,2008,35(3)：344-345.
[3]梁颖瑜,潘毅,徐志伟等.“调肝肾、祛痰瘀”治法早期干预自发性高血压大鼠子鼠血压及VSMC钙离子浓度的影响.医学信息杂志,2003,16(7)：398-400.
[4]卢焯明,潘毅,梁颖瑜等.调肝肾、祛痰瘀治法提前干预对SHR血压及血管活性物质的影响.中国中医药信息杂志,2004,11(9)：780-782.
[5]潘毅,吴丽丽,严灿等,活血祛痰法对自发性高血压大鼠心肌线粒体膜的影响.广州中医药大学学报,2001,18(1)：60-62.
[6]邓中炎,严灿,潘毅等.平肝益气、活血祛痰法逆转自发性高血压大鼠左室重构的实验研究.中国中医药科技,2001,8(2)：106-107.
[7]李剑,潘毅,严灿等.滋补肝肾、活血祛痰方药对原发性高血压大鼠左心室肥厚的影响.山西中医,2003,19(2)：54-56.
[8]沈云辉,曹玉净,崔瑛,等.熟地黄对拟痴呆模型小鼠记忆力的影响及机制研究[J].上海中医药杂志,2007,41(4)：67.
[9]崔豪,冯静,崔瑛,等.熟地黄及其多糖中枢抑制作用研究[J].河南中医学院学报,2006,21(127)：18.
[10]蔡永敏,任玉让,王黎,等.最新中药药理与临床应用.华夏出版社,1999,1：287-508.
[11]冉先德.中华药海[M].哈尔滨出版社,1993,4：511-540.
[12]唐利辉,王孝铭,梁殿权.丹参素对大鼠心肌缺血再灌注损伤的保护作用[J].中国病理生理杂志,1989,5(2)：65.
[13]李仪奎.中药药理学.中国中医药出版社,1992：135-136.
[14]邹正午,徐理纳,田津英.迷迭香酸抗血栓和抗血小板聚集的作用[J].药学学报,1993,28(4)：241.
[15]徐理纳.丹参多种水溶性成分抗氧化作用[A].中国中西医结合会活血化瘀研究会.血瘀症和活血化瘀[C].北京：学苑出版社,1990,77-78.
[16]柳锋,郑智,丹参预防自发性高血压大鼠左室肥厚及对转移生长因子的影响,中国急救医学,2003,2(23)：71-72.
[17]蒋文跃,杨宇,李燕燕.化痰药半夏、瓜蒌、浙贝母、石菖蒲对大鼠血液流变性的影响.中医杂志,2002,43(3)：215-216.
[18]吴波,曹红,陈思维等.瓜蒌提取物对缺血缺氧及缺血后再灌注损伤心肌的保护作用.沈阳药科大学学报,2000,17(6)：450-451.
[19]贺立圊.瓜蒌、薤白降脂作用的析因研究.湖南中医药导报,2002,8(4)：205.
[20]刘青云.中药药理学.北京：人民卫生出版社,1997,1：89,114-120.
[21]王作祥等.中草药,1983,14(3)：29.
[22]张子熙等.药学学报.1980,15(7)：385.
[23]王东甲等.中国药理学报.1984,5(3)：181.
[24]陈重华,粟晓黎,张俊霞.三七皂苷R1、人参皂苷Rd对微循环及凝血作用的影响.华西医大学报,2002,33(4)：550-552.
[25]郑颖,徐治国.人参与三七的药效学比较研究.中药药理与临床,2000,16(5)：22-24.
[26]李英兰等.肾素血管紧张素系统、内皮素及降钙素基因相关肽在肾性高血压大鼠的动态变化[J].青海医学院学报.2005,1(26)：47-48.
[27]Hitomi, Hirofumi a, Kiyomoto, Hideyasu a, et al. Angiotensin Ⅱ and oxidative stress[J]. Current Opinion in Cardiology.2007,22(4):311-315.
[28]Seccia, Teresa M a, Maniero, Carmen a, et al. Role of angiotensin Ⅱ, endothelin-1 and L-type calcium channel in the development of glomerular, tubulointerstitial and perivascular fibrosis[J]. Journal of Hypertension.2008,26(10):2022-2029.
[29]王晋明,胡钢英,李庚山,等.氯沙坦对自发性高血压大鼠阻力血管结构的影响.高血压杂志,2001,9(1)：58.
[30]丁虎,周期,邓军,等.易卒中型自发性高血压大鼠中枢和血管中紧张素Ⅱ与血压变化的关系.生理学报,1990；42：61.
[31]Vicant E. Hypertension and the microcirculation a brief overview of experimental studies. Hypertens,1990,10(supp15):559.
[1]Meijs MF, de Windt LJ, de Jonge N, et al. Left ventricular hypertrophy:a shift in paradigm. Curr Med Chem,2007,14(2):157-171.
[2]Devereux RB, Bella JN, Palmieri V, et al. Hypertension Genetic Epidemiology Network Study Group. Left ventrieular systolic dysfunction in a biracial sample of hypertensive adults:The Hypertension Genetic Epidemiology Network (HyperGEN) Study. HyPertension 2001,38(3):417-423.
[3]Dickhout JG, Lee RM. Structural and functional analysis of small arteries from young spontaneously hypertensive rats. Hypertension.1997,29(3):781-789.
[4]Mifune M, Sasamura H, Shimizu—irota R, et al. Angiotensin II type 2 receptors stimulate collagen synthesis in cultured vascular smooth muscle cells. Hypertension, 2000,36(5):845-850.
[5]Rizvi MA, Katwa L, Spadone DP, et al. The effects of endothelin-1 on collagen type I and type III synthesis in cultured porcine coronary artery vascular smooth muscle cells. J Mol Cell Cardiol.1996,28(2):243-252.
[6]Matsumura S, Kawazoye S, Tian SF, et al. Biochemical characterization of the fibers of collagen and elastin in the aortic wall of SHR. SP Clin Exp Pharmacol Physiol Suppl, 1995,22(1):S136-138.
[7]Veniant M, Gray GA, Heudes D, et al. Structural changes and cyclic GMP content of the aorta after calcium antagonism or angiotensin converting enzyme inhibition in renovascular hypertensive rats. J Hypertens,1995,13(7):731-737.
[8]Ling S, Dai A, Ma YH, et al. Matrix-dependent gene expression of egr—1 and PDGFA regulate angiotensin Ⅱ induced proliferation in human vascular smooth muscle cells. Hypertension,1999,34(5):1141-1146.
[9]秦旭平,龙光,徐立朋,等.氯沙坦和培哚普利逆转高血压大鼠心血管重构的比较[J].中国药理学通报,2004,20(10)：1107-1111.
[10]Trippodo NC, Frohlich ED. Similarities of genetic (spontaneous)hypertension. Man and rat. Circ Re,1981,48(3):309-319.
[11]Pravenec M, Zidek V, Landa V, et al. Genetic analysis of cardiovascular risk factor clustering in spontaneous hypertension. Folia Biol(Praha).2000; 46(6):233-240.
[12]Yagil Y, Yagil C. Genetic models of hypertension in experimental animals. Exp Nephrol, 2001,9(1):1-9.
[1]Cohen JS, Hogan ME. The new genetic medicines. Sci Am,1994,271:76-85.
[2]Rohenkerg M, Johnson G, laughlin C, et al. Oligodeoxy nucleotides as antisense inhibitors of gene expression:Therapeutie implications. J Natl Cancer Inst,1989,81: 1539-1544
[3]刘智敏,韩梅,温进坤.粘着斑相关非激酶对骨桥蛋白促血管平滑肌细胞迁移的抑制作用及分子机制[J].中国生物化学与分子生物学报,2004,20(1)：131-137.
[4]刘智敏,韩梅,温进坤.细胞外基质促血管平滑肌细胞迁移及β3整合素和粘着斑激酶表达[J].中国病理生理杂志,2003,19(2)：163-166.
[5]王博,张继东,冯进波,等.芩丹胶囊对自发性高血压大鼠血管重塑以及骨桥蛋白基因表达的影响[J].南京中医药大学学报,2007,23(3)：157-160.
[6]石缨,温进坤.新生小牛血清、碱性成纤维细胞生长因子和肝素对大鼠血管平滑肌细胞骨桥蛋白基因表达的影响[J]. 中国动脉硬化杂志,1999,7：1-3.
[7]Wang X, Louden C, Ohlstein EH, et al. Osteopontin expression in platelet-derived growth factor stimulated vascular smooth muscle cells and carotid artery after balloon angioplasty[J]. Arterioscler Throrab Vasc Biol,1996,16(11):365-372.
[8]傅国香,朱鼎良,刘建军,等.骨桥蛋白参与血管紧张素Ⅱ诱导的血管平滑肌细胞迁移.高血压杂志,2006,14(4)：277-280.
[9]姜志胜,符民桂,赵文,等.一氧化氮及一氧化碳对碱性成纤维细胞生长因子促血管平滑肌细胞增殖作用的影响.北京医科大学学报,1999,12(6)：524-527.
[10]张瑶,郭文怡,王臻,等.一氧化氮对大鼠主动脉血管平滑肌细胞骨桥蛋白表达的影响.医学研究杂志,2008,37(12)：75-78.
[1]Fraga-Silva R A, Pinheiro S V, Goncalves A C, et al. The antithrombotic effect of angiotensin-(1-7) involves mas-mediated NO release from platelets [J].Mol Med,2008, 14(1-2):28-35.
[2]Chappel M C, Ferrario C M. ACE and ACE2:their role to balance the expression of angiotensin-Ⅱ and angiotensin-(1-7) [J].Kidney Int,2006,70(1):8-10.
[3]Fernandes L, Fortes ZB, NigroD, et al. Potentiation of bradykinin by angiotensin-(1-7) on arterioles of spontaneously hypertensive rats studied in vivo [J]. Hypertension,2001, 37(2 Part 2):703-709.
[4]Zhong JC, Huang IY, Yang YM, et al. Upregulation of anglotensin converting enzyme 2 by all trans retinoic acid in sponta neously hypertensive rats[J]. Hypertension,2004,44: 907-912.
[5]Strazzullo P, Galletti F. Impact of the renin-angiotensin system on lipid and carbohydrate metabolism[J]. Curropin Nephrol Hypertens,2004,13:325-332.
[6]Schmaier AH. The Kallikrein and the rennin-angiotensin systems have a muhilayered interact ion[J]. Am J Physiol Regulatory Integrative Comp Physiol,2003,285:1-13.
[7]Santos RASD, Passaglio KT, Pesquero JB, et al. Interactions between angiotensin (1-7), kinins and angiotensin II in kidney and blood vessels [J]. Hypertension,2001,38:660-664.
[8]Maia G, Ramos MC, Fernandes I, et al. Angiotensin(l-7) antagonist A-779 attenuates the potentiation of brady kinin by captopril in rats[J]. J Cardiovasc harmacol,2004,43: 685-691.
[9]许昌声,翁智远,王华军,等.SHR,WKY大鼠心,肾及胸主动脉ACE, ACE2表达的差异与高血压的关系.中国比较医学杂志,2006,7(16)：402-407.
[10]林杰,田海红,秦旭平,等.氯沙坦对肾性高血压大鼠血管中ACE2 mRNA和蛋白质表达水平的影响.中南药学,2010,1(8)：6-10.
[11]Bernard I, Levy. How to Explain the Differences Between Renin Angiotensin System Modulators [J]. American Journal of Hypertension,2005,18(9):134-141.
[12]Sravros Apostolakis, Elias Krambovitis, Zaharenia Vltats, et al. CX3CR1 receptor is up-regulated in monocytes of coronary artery diseased patients:Impact of pre-inflammatory stimuli and rennin angiotensin system modultors [J]. Thrombosis Research,2007,121(3):387-395.
[2]唐培位.高血压病气虚证中医辩证施治探微.新疆中医药,2011,19(2)：7-8.
[3]刘桂林.高血压病气虚机制浅析[J].山东中医杂志,2003,22(1)：9-10.
[4]邓国琼,邓德强.益气升清法在高血压病中的运用[J].中国中医药信息杂志,2007,14(9)：79.
[5]袁卫红,贺泽龙.高血压病的辨病辨证治疗思路探讨[J].湖南中医药导报,2000,6(5)：10-11.
[6]李青鸟.原发性高血压病病因之我见[J].光明中医,2000,15(1)：8-11.
[7]李雪苓,韩宁林,周大勇等.养阴活血法治疗阴虚阳亢型原发性高血压的临床研究[J].安徽中医学院学报,2007,26(4)：10.
[8]郑林.高血压病的中医研究评析[J].中医药学刊,2003,21(12)：2131.
[9]郭世平,何鲜平,林秀美,等.加味半夏白术天麻汤治疗原发性痰浊中阻型高血压60例[J].陕西中医,2006,27(7)：797-798.
[10]孟庆刚,魏成,帕丽旦,等.试论痰瘀同源[J].山东中医杂志,2006,25(7)：443-445.
[11]徐树楠,刘海丽.高血压病的中医病理学特点探微[J].中国中医基础医学杂志,2003,9(9)：10.
[12]李武明,何玉香,谭元生.复方杜仲降压片治疗高血压病45例分析[J].中医药学,2004,22(2)：33卜332.
[13]韩学杰,朱研,李成卫.原发性高血压病中医病因理论探讨[J].医学研究杂志,2007,36(8)：6.
[14]徐树楠,张再康.从瘀论治高血压病探讨[J].中国中医基础医学杂志,2004,8(10)：38.
[15]靳立民.原发性高血压病的中医病机探讨[J].亚太传统医药,2005,2：40.
[16]韩学杰,沈宁.毒损心络与高血压病[J].中医杂志,2005,46(2)：155-156.
[17]王丹,杨振伟.高血压病基本证型与血瘀的相关性研究[J].江西中医学院学报,2007,19(1)： 54-56.
[18]李成卫.原发性高血压病痰瘀同治整体治疗方案设计[J].中国医药学报,2004,19(10)：626.
[19]于向东,崔军.从络论治高血压的理论探讨[J].中国临床康复,2003,24(7)：3364-3365.
[20]邓中炎,徐志伟,陈群,等.中医基础理论体系现代研究.广州：广东科技出版社,2002,1：7,88,193.
[21]叶任高.内科学.北京：人民卫生出版社,2002,5：258-261.
[22]邓铁涛.邓铁涛医学文集.北京：人民卫生出版社,2001,1：19.
[23]肖梅芳,周端.活血潜阳颗粒对自发性高血压大鼠血浆肾素血管紧张素系统的影响[J].上海中医药杂志,2007,41(7)：59.
[24]牟林茂,李安源,司国民,等.平肾通络降压颗粒对自发性高血压大鼠血压及肾素-血管紧张素系统的影响[J].中国中医药信息杂志,2008,15(12)：36.
[25]靳宏光,黄永生.夏膝口服液对自发性高血压大鼠肾素血管紧张素Ⅱ水平的影响[J].中华中医药学刊,2007,25(5)：1019-1021.
[26]尚明月.地黄降压汤对肾性高血压大鼠血压及血浆血管紧张素Ⅱ、醛固酮影响的实验研究.吉林大学学报,2007,1：1.
[27]李建平,严灿,邓中炎,等.活血祛痰方药预防自发性高血压大鼠心肌纤维化实验研究[J].中医杂志,2000,41(5)：301-302.
[28]粱颖瑜,潘毅,徐志伟,等.“调肝肾、祛痰瘀”治法早期干预自发性高血压大鼠子鼠血压及VSMC钙离子浓度的影响[J].医学信息,2003,16(7)：398-400.
[29]许东元,金东洙,金范学.三黄泻心汤水提取液对大鼠离体胸主动脉环的舒张作用及机制[J].四川中医,2008,26(10)：11.
[30]郑非,李树青.通心络对自发性高血压大鼠血管内皮功能的影响[J].中西医结合心血管病杂志,2009,7(2)：179.
[31]葛华,赵英莉,王璇,等.通心络对高血压大鼠血管内皮功能保护作用的研究.首届国际络病学大会论文集.北京.中国.2005.第1卷.
[32]刘真,于慧卿,魏运湘,等.夏枯草汤治疗高血压病及对血管内皮功能的影响[J].陕西中医,2006,27(2)：162.
[33]武文辉,吉中强,纪文岩.新血府逐瘀汤对高血压大鼠内皮功能及血栓前状态影响[J].中西医结合心血管病杂志,2007,5(11)：1084.
[34]李辉,徐贵成,刘坤,等.息化饮2号对高血压模型大鼠的降压实验及活血化瘀作用研究.北京中医药大学学报,2003,26(4)：47.
[35]陈利群.健脾化痰活血祛瘀法对痰瘀互阻型原发性高血压病患者血脂和血液流变学的影响.河北中医,2005,27(2)：93-95.
[36]金雪元.高血压病与胰岛素抵抗的研究进展.中国优秀硕士学位论文全文数据库,2008,(1)：1.
[37]杨晔,王志国,王浩,等.金芪降糖片对胰岛素抵抗和高血压的影响.天津医药,2005,33(5)：298-230.
[38]司晓晨,播杨,程海波等.胰敏胶囊阻止果糖诱导的胰岛素抵抗大鼠高血压的发生研究.中医药学刊,2004,22(2)：250-252.
[39]徐京育,苏润泽,张良.复方槐花降压冲剂治疗胰岛素抵抗性高血压[J].中西医结合心脑 血管病杂志,2005,3(6)：489-490.
[40]熊一力,王嘉陵,钱家庆.莲心碱对内皮素促血管平滑肌细胞增殖及原癌基因表达的影响[J].中国现代医学杂志,1999,9(2)：1-3.
[41]邓杰,熊玮,郑智.丹参对自发性高血压大鼠心肌细胞凋亡及基因蛋白表达的影响[J].江西医药,2003,38(5)：322-324.
[42]张茗,李敬孝,益心胶囊对肾性高血压大鼠左室肥厚及c-fos基因表达的影响[J].中医药信息,2008,25(2)：57-58.
[43]Suzanne Oparil Michael A, Weber. Hypertension[M]. 北京：北京大学医学出版社,2008: 265.
[44]Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocrine Reviews,2003,24: 261-271.
[45]Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensinⅠto angiotensin 1-9. Circ Res.2000,87(5): E1-E9.
[46]DonoghueM, HsiehF, Baronas E, et al. A novel angiotensin converting enzyme related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Cir Res,2000,87: el-e9.
[47]Gallagher PE, Chappell MC, Bernish WB, et al. ACE2 expression in brain:angiotensin II down-regulates ACE2 in astrocytes. Hypertension,2003,42:389.
[48]Giner V, Poch E, Bragulat E, el al. Renin-angiotensin system genetic polymorphisms and salt sensitivity in essential hypertension, Hypertension,2000,35:512-517.
[49]Tamaki S, Nakamura Y, Tsujita Y, et al. Polymorphism of the angiotensin converting enzyme gene and blood Pressure in a Japanese general population (the Shigaraki Study), Hypertens Res,2002,25:843-848.
[50]Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase, J Biol Chem,2002,277:4838-4843.
[51]Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function, Nature, vol.2002,417:822-828.
[52]Gurley SB, Allred A, Le TH, et al. Altered blood Pressure responses and normal cardiac phenotype in ACE2-null mice, J Clin Invest,2006,116:2218-2225.
[53]Tikellis C, CooPer ME, Bialkowski K, et al. Developmental expression of ACE2 in the SHR kidney:a role in hypertension? Kidney Int,2006,70:34-41.
[54]Rentzseh B, TOdiras M, Iliescu R, et al. Transgenic angiotensin-converting enzyme 2 over expression in vessels of SHR SP rats reduces blood pressure and improves endothelial function, Hypertension,2008,52:967-973.
[56]王向宇,吴可贵,张更等.自发性高血压大鼠高血压形成前期血管平滑肌细胞增殖和肾素-血管紧张素系统的关系.中华心血管病杂志,1997,25(3)：225-228.
[57]Kiliszek M, Burzynska B, Styczynski G, et al. A1166C polymorphism of the angiotensin ATI receptor(ATl R)gene alters endothelial response to statin treatment[J]. Clin Chem Lab Med,2007,45(7):839-842.
[58]Rehmn A, Rasool AH, Naing L, et al. Influence of the Angiotensin Ⅱtpye 1 receptor genel166A>C polymorphismon BP nadaortic pulse wave velocity among MaLays[J]. Ann Hum Genet,2007,71 (Pt 1):86-95.
[59]Schulman IH, Raij L. The angiotensin II type 2 receptor:what is its clinical significance[J]. Curr Hypertens Rep.2008,10(3):188-193.
[60]Widdop RE, Vinh A, HenriON, et al. Vascular angiotensin AT2 receptors in hypertension and ageing[J]. Clin Exp Pharmacol Physiol,2008,35(9):386-390.
[61]Yayama K, Horii M. Hiyoshi H, et al. Up-regulation of angiotensinIItype 2 receptor in rat thoracic by aorta by pressure overload[J]. J Pharmacol Exp Ther,2004,308(2): 736-743.
[62]Cines DB, Pollak ES, Buck C, Loscalzo J, Zimmerman GA, McEver RP, et aL. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood,1998,91: 3527-3561.
[63]Rekhviashvili A, Abashidze R. The relationship between endothelial dysfunction and 24-hour blood pressure rhythm in patients with arterial hypertension[J]. Georgian Med News,2008, (155):13-17.
[64]陈维洲.血管内皮细胞舒缩血管物质与心血管疾病[J].生物科学信息,1991,3：25-23.
[65]Mccarty MF. UP-regulation of endothelial nitric oxide activity as a central strategy prevention of ischemie stroke-just say NO to stroke[J]. Med HyPotheses,2000,55(5): 386-403.
[66]Yang Z, Venardos K, Jones E, et al. Identification of a novel polymorphism in the 3'UTR of the L-arginine transporter gene SLC7AI Contribution to hypertension and endothelial dysfunction[J]. Circulation,2007,115:1269-1274.
[67]韩若凌.一氧化氮、内皮素与原发性高血压的关系[J].河北医药,1998,20(1)：16-19.
[68]Cai H, Davis ME, Drummond GR Harrison DG Induction of endothelial NO synthase by hydrogen peroxide via a Ca2+/calmodulin-dependent protein kinas alias kinase 2-dependent pathway. Artcrioscler Thromb Vase Biol,2001,21:1571-1576.
[69]Rubanyi GM. The role of endthelium in cardiovascular homeostasis and diseases [J].J Cardiovasc Pharmacol,1993,22(suppl 4):S1-S14.
[70]Unger T, Ganten D, Lang RE. Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? studies with the two different compounds. HOE-498 and MK-421 in spontaneously hypertensive rats [J].J Cardiovase Pharmacol,1994,6:872-880.
[71]丛洪良,黄体钢,周丽娟,等.NO,AngⅡ对大鼠主动脉内皮细胞功能及形态学影响的实验研究.高血压杂志,2007(4)：374-375.
[72]Franco C, Ho B, Mulholland D, et al. Doxycycline alters vascular smooth muscle cell adhesion, migration, and reorganization of fibrillar collagen matrices[J].Am J Pathol. 2006,168(5):1697-709.
[73]Reape T J. IGF-1 increases b-FGF-induced mitogenesis and up regulates FGFR-1 in rabbits VSMC[J]. Am j Physiol,1996,270(4):1141.
[74]Peoples GE, Blotnick S, Takahashi K, et al. T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor:a potential pathologic role. Proc Natl Acad Sci USA,1995:92(14):6547-6551.
[75]Eckenstein FP. Fibroblast growth factors in the nervous system. Neuro,1994, 5(18):467-480.
[76]Cuevas P, Carceller F, ortega S, et al. Hypertensive activity of fibroblast growth factor. Sei USA,1991,254:2108-2109.
[77]王晓红,姜志胜,迪丽努尔,等.碱性成纤维细胞生长因子对兔血管舒张功能及左旋精氨酸／一氧化氮途径的影响[J].中国病理生理杂志,1999,15(3)：245.
[78]Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopentin):an early component of type-1 (cell-mediated)in munity[J]. Science,2000,287(5454):860-4.
[79]Hotte SJ, Winquist EW, Stitt L, et al. Plasma osteopontin associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma[J]. Cancer, 2002,95:506-512.
[80]Giachelli C, Bae N, Lombardi D, et al. Molecular cloning and characterization of 287, a rat mRNA which distinguishes smooth muscle cell phenotypes in vitro and is identical to osteopontin(secreted phosphoprotein I,2aR). Biochem Biophys Res Commun,1991,177(2): 867-873.
[81]Chaulet H, Desgranges C, Renault MA, et al. Extracellular nucleotides induce arterial smooth muscle cell migration via osteopontin[J]. Circ Res,2001,89(9):772-778.
[82]Panda D, Kundu GC, Lee BI, et al. Potential roles of osteopontin and alphaVbeta3 angioplasty. integrin in the development of coronary artery restenosis after Proc Natl Acad Sci USA.1997,94(17):9308-9813.
[83]Rebsamen MC, Sun J, Norman AW, et al.I alpha,25-dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ Res, 2002,91(1):17-24.
[84]Weintraub AS, Schnapp LM, Lin X, et al. Osteopontin deficiency in rat vascular smooth muscle cells is associated with an inability to adhere to collagen and increased apoptosis [J]. Lab Invest,2000,80(11):1603-1615.
[85]Schlaepfer DD, Jones KC, Hunter T. Multiple Grb2-mediated integrin-stimulated signaling pathways to ERKZ/mitogen-activated protein kinase:summation of bothc-Src-and focal adhesion kinase-initiated tyrosine phosphorylation events. Mol Cell Biol,1998, 18(5):2571-2585.
[86]Renault MA, Jalvy S, Belloc I, et al. AP-1 is involved in UTP-induced osteopontin expression in arterial smooth muscle cells[J]. Circ Res,2003,93(7):674-681.
[87]Lauer MS, Anderson KM, Kannel W, et al. The impact of obesity on left ventriculammss and geometry, the frammgham study. JAMA,2009,226:231.
[88]Yamazaki T, Komuro I, Kudoh S, et al. Angiotensin Ⅱ partly mediates mechaical stressinduce D cardial hypertroph. GRRes,2008,77:258.
[89]Kent T, Hooberk S, Cooper VG. Loadresonses of protein synthesis in adult mammalian myocardium:role of cardiac defor-mation linked to sodium in flux. Cir Res,2008,64: 72.
[90]Cripis TR, Malik M, Faffell TG, et al. Prognostic value of reuced heart rate variability after myocardial infarction:clinical evaluation of a new analysis method. Br Heart J, 2009,65:96.
[90]Smajilovic S. Novel role of the calcium-sensing receptor in blood pressure modulation. Hypertension,2008,52:994-1000.
[91]Shonghnessy KM, Karet. Salt handling and hypertension. Annu Rev Nutr,2006,26: 343-365.
[92]lawes CM, Vander Hooms, Rodrgers A. Global burden of blood pressure related disease. Lancet,2008,371:1513-1518.
[93]Sarafidis AP, Bakris GL. Resistant hypertension:an overview of evaluation and treatment. J Am coll cardiol,2008,52:1749-1757.
[1]戴勇,彭武建,徐卓佳.“两肾一夹”肾性高血压大鼠模型的改进[J].实验动物科学与管理,2006,2(23)：60-62.
[2]曹珊珊,李瑞芳,方伟进,等.肾性高血压大鼠模型制作的改良方法.河南科技大学学报(医学版),2010,3(28)：165-167.
[3]顾德官,顾天华,宋代军,等.试验性高血压大鼠的血压观察.上海第二医学院学报,1985,2：102-104.
[4]Sun ZJ, Zhang ZE. Historic perspectives and recent advances in major animal models of hypertension. Acta Pharmacol Sin,2005,26(3):295-301.
[5]Pravenec M, Zidek V, Landa V, et al. Genetic analysis of cardiovascular risk factor clustering in spontaneous hypertension. Folia Biol(Praha).2000,46(6):233-240.
[6]Mann JF, Phillips.MI, Dietz R, et al. Effects of central and peripheral angiotensin blockade in hypertensive rats. Am J Physiol.1978,234(5):H629-637.
[7]Trippodo NC, Frohlich ED. Similarities of genetic(spontaneous) hypertension. Man and rat. Circ Re,1981,48(3):309-319.
[8]Yagil Y, Yagil C. Genetic models of hypertension in experimental animals. Exp Nephrol, 2001,9(1):1-9.
[9]James 0 Davis, et al. Pathogenesis of chronic renovascular hypertension. Circulation Research,1977,40:399.
[10]傅继华,陈宇飞,张琪.肾性高血压大鼠实验模型制作改进[J].中国药科大学学报,1995,26(6)：383-384.
[11]孙琪,黄荣桂,郑兴中,等.一肾一夹肾血管性高血压动物模型的制作[J].临床军医杂志,2007,35(6)：812-814.
[1]潘毅,蔡三郎,柳琳,调肝肾祛痰瘀复方含药血清对SHR血管平滑肌细胞肾素-血管紧张素系统的影响.中华中医药学刊,2009,27(6)：1135-1139.
[2]潘毅,柳琳,蔡三郎等.调肝肾祛痰瘀复方发病前不同时段给药对SHR血管重构的整体药效学 研究.辽宁中医杂志,2008,35(3)：344-345.
[3]梁颖瑜,潘毅,徐志伟等.“调肝肾、祛痰瘀”治法早期干预自发性高血压大鼠子鼠血压及VSMC钙离子浓度的影响.医学信息杂志,2003,16(7)：398-400.
[4]卢焯明,潘毅,梁颖瑜等.调肝肾、祛痰瘀治法提前干预对SHR血压及血管活性物质的影响.中国中医药信息杂志,2004,11(9)：780-782.
[5]潘毅,吴丽丽,严灿等,活血祛痰法对自发性高血压大鼠心肌线粒体膜的影响.广州中医药大学学报,2001,18(1)：60-62.
[6]邓中炎,严灿,潘毅等.平肝益气、活血祛痰法逆转自发性高血压大鼠左室重构的实验研究.中国中医药科技,2001,8(2)：106-107.
[7]李剑,潘毅,严灿等.滋补肝肾、活血祛痰方药对原发性高血压大鼠左心室肥厚的影响.山西中医,2003,19(2)：54-56.
[8]沈云辉,曹玉净,崔瑛,等.熟地黄对拟痴呆模型小鼠记忆力的影响及机制研究[J].上海中医药杂志,2007,41(4)：67.
[9]崔豪,冯静,崔瑛,等.熟地黄及其多糖中枢抑制作用研究[J].河南中医学院学报,2006,21(127)：18.
[10]蔡永敏,任玉让,王黎,等.最新中药药理与临床应用.华夏出版社,1999,1：287-508.
[11]冉先德.中华药海[M].哈尔滨出版社,1993,4：511-540.
[12]唐利辉,王孝铭,梁殿权.丹参素对大鼠心肌缺血再灌注损伤的保护作用[J].中国病理生理杂志,1989,5(2)：65.
[13]李仪奎.中药药理学.中国中医药出版社,1992：135-136.
[14]邹正午,徐理纳,田津英.迷迭香酸抗血栓和抗血小板聚集的作用[J].药学学报,1993,28(4)：241.
[15]徐理纳.丹参多种水溶性成分抗氧化作用[A].中国中西医结合会活血化瘀研究会.血瘀症和活血化瘀[C].北京：学苑出版社,1990,77-78.
[16]柳锋,郑智,丹参预防自发性高血压大鼠左室肥厚及对转移生长因子的影响,中国急救医学,2003,2(23)：71-72.
[17]蒋文跃,杨宇,李燕燕.化痰药半夏、瓜蒌、浙贝母、石菖蒲对大鼠血液流变性的影响.中医杂志,2002,43(3)：215-216.
[18]吴波,曹红,陈思维等.瓜蒌提取物对缺血缺氧及缺血后再灌注损伤心肌的保护作用.沈阳药科大学学报,2000,17(6)：450-451.
[19]贺立圊.瓜蒌、薤白降脂作用的析因研究.湖南中医药导报,2002,8(4)：205.
[20]刘青云.中药药理学.北京：人民卫生出版社,1997,1：89,114-120.
[21]王作祥等.中草药,1983,14(3)：29.
[22]张子熙等.药学学报.1980,15(7)：385.
[23]王东甲等.中国药理学报.1984,5(3)：181.
[24]陈重华,粟晓黎,张俊霞.三七皂苷R1、人参皂苷Rd对微循环及凝血作用的影响.华西医大学报,2002,33(4)：550-552.
[25]郑颖,徐治国.人参与三七的药效学比较研究.中药药理与临床,2000,16(5)：22-24.
[26]李英兰等.肾素血管紧张素系统、内皮素及降钙素基因相关肽在肾性高血压大鼠的动态变化[J].青海医学院学报.2005,1(26)：47-48.
[27]Hitomi, Hirofumi a, Kiyomoto, Hideyasu a, et al. Angiotensin Ⅱ and oxidative stress[J]. Current Opinion in Cardiology.2007,22(4):311-315.
[28]Seccia, Teresa M a, Maniero, Carmen a, et al. Role of angiotensin Ⅱ, endothelin-1 and L-type calcium channel in the development of glomerular, tubulointerstitial and perivascular fibrosis[J]. Journal of Hypertension.2008,26(10):2022-2029.
[29]王晋明,胡钢英,李庚山,等.氯沙坦对自发性高血压大鼠阻力血管结构的影响.高血压杂志,2001,9(1)：58.
[30]丁虎,周期,邓军,等.易卒中型自发性高血压大鼠中枢和血管中紧张素Ⅱ与血压变化的关系.生理学报,1990；42：61.
[31]Vicant E. Hypertension and the microcirculation a brief overview of experimental studies. Hypertens,1990,10(supp15):559.
[1]Meijs MF, de Windt LJ, de Jonge N, et al. Left ventricular hypertrophy:a shift in paradigm. Curr Med Chem,2007,14(2):157-171.
[2]Devereux RB, Bella JN, Palmieri V, et al. Hypertension Genetic Epidemiology Network Study Group. Left ventrieular systolic dysfunction in a biracial sample of hypertensive adults:The Hypertension Genetic Epidemiology Network (HyperGEN) Study. HyPertension 2001,38(3):417-423.
[3]Dickhout JG, Lee RM. Structural and functional analysis of small arteries from young spontaneously hypertensive rats. Hypertension.1997,29(3):781-789.
[4]Mifune M, Sasamura H, Shimizu—irota R, et al. Angiotensin II type 2 receptors stimulate collagen synthesis in cultured vascular smooth muscle cells. Hypertension, 2000,36(5):845-850.
[5]Rizvi MA, Katwa L, Spadone DP, et al. The effects of endothelin-1 on collagen type I and type III synthesis in cultured porcine coronary artery vascular smooth muscle cells. J Mol Cell Cardiol.1996,28(2):243-252.
[6]Matsumura S, Kawazoye S, Tian SF, et al. Biochemical characterization of the fibers of collagen and elastin in the aortic wall of SHR. SP Clin Exp Pharmacol Physiol Suppl, 1995,22(1):S136-138.
[7]Veniant M, Gray GA, Heudes D, et al. Structural changes and cyclic GMP content of the aorta after calcium antagonism or angiotensin converting enzyme inhibition in renovascular hypertensive rats. J Hypertens,1995,13(7):731-737.
[8]Ling S, Dai A, Ma YH, et al. Matrix-dependent gene expression of egr—1 and PDGFA regulate angiotensin Ⅱ induced proliferation in human vascular smooth muscle cells. Hypertension,1999,34(5):1141-1146.
[9]秦旭平,龙光,徐立朋,等.氯沙坦和培哚普利逆转高血压大鼠心血管重构的比较[J].中国药理学通报,2004,20(10)：1107-1111.
[10]Trippodo NC, Frohlich ED. Similarities of genetic (spontaneous)hypertension. Man and rat. Circ Re,1981,48(3):309-319.
[11]Pravenec M, Zidek V, Landa V, et al. Genetic analysis of cardiovascular risk factor clustering in spontaneous hypertension. Folia Biol(Praha).2000; 46(6):233-240.
[12]Yagil Y, Yagil C. Genetic models of hypertension in experimental animals. Exp Nephrol, 2001,9(1):1-9.
[1]Cohen JS, Hogan ME. The new genetic medicines. Sci Am,1994,271:76-85.
[2]Rohenkerg M, Johnson G, laughlin C, et al. Oligodeoxy nucleotides as antisense inhibitors of gene expression:Therapeutie implications. J Natl Cancer Inst,1989,81: 1539-1544
[3]刘智敏,韩梅,温进坤.粘着斑相关非激酶对骨桥蛋白促血管平滑肌细胞迁移的抑制作用及分子机制[J].中国生物化学与分子生物学报,2004,20(1)：131-137.
[4]刘智敏,韩梅,温进坤.细胞外基质促血管平滑肌细胞迁移及β3整合素和粘着斑激酶表达[J].中国病理生理杂志,2003,19(2)：163-166.
[5]王博,张继东,冯进波,等.芩丹胶囊对自发性高血压大鼠血管重塑以及骨桥蛋白基因表达的影响[J].南京中医药大学学报,2007,23(3)：157-160.
[6]石缨,温进坤.新生小牛血清、碱性成纤维细胞生长因子和肝素对大鼠血管平滑肌细胞骨桥蛋白基因表达的影响[J]. 中国动脉硬化杂志,1999,7：1-3.
[7]Wang X, Louden C, Ohlstein EH, et al. Osteopontin expression in platelet-derived growth factor stimulated vascular smooth muscle cells and carotid artery after balloon angioplasty[J]. Arterioscler Throrab Vasc Biol,1996,16(11):365-372.
[8]傅国香,朱鼎良,刘建军,等.骨桥蛋白参与血管紧张素Ⅱ诱导的血管平滑肌细胞迁移.高血压杂志,2006,14(4)：277-280.
[9]姜志胜,符民桂,赵文,等.一氧化氮及一氧化碳对碱性成纤维细胞生长因子促血管平滑肌细胞增殖作用的影响.北京医科大学学报,1999,12(6)：524-527.
[10]张瑶,郭文怡,王臻,等.一氧化氮对大鼠主动脉血管平滑肌细胞骨桥蛋白表达的影响.医学研究杂志,2008,37(12)：75-78.
[1]Fraga-Silva R A, Pinheiro S V, Goncalves A C, et al. The antithrombotic effect of angiotensin-(1-7) involves mas-mediated NO release from platelets [J].Mol Med,2008, 14(1-2):28-35.
[2]Chappel M C, Ferrario C M. ACE and ACE2:their role to balance the expression of angiotensin-Ⅱ and angiotensin-(1-7) [J].Kidney Int,2006,70(1):8-10.
[3]Fernandes L, Fortes ZB, NigroD, et al. Potentiation of bradykinin by angiotensin-(1-7) on arterioles of spontaneously hypertensive rats studied in vivo [J]. Hypertension,2001, 37(2 Part 2):703-709.
[4]Zhong JC, Huang IY, Yang YM, et al. Upregulation of anglotensin converting enzyme 2 by all trans retinoic acid in sponta neously hypertensive rats[J]. Hypertension,2004,44: 907-912.
[5]Strazzullo P, Galletti F. Impact of the renin-angiotensin system on lipid and carbohydrate metabolism[J]. Curropin Nephrol Hypertens,2004,13:325-332.
[6]Schmaier AH. The Kallikrein and the rennin-angiotensin systems have a muhilayered interact ion[J]. Am J Physiol Regulatory Integrative Comp Physiol,2003,285:1-13.
[7]Santos RASD, Passaglio KT, Pesquero JB, et al. Interactions between angiotensin (1-7), kinins and angiotensin II in kidney and blood vessels [J]. Hypertension,2001,38:660-664.
[8]Maia G, Ramos MC, Fernandes I, et al. Angiotensin(l-7) antagonist A-779 attenuates the potentiation of brady kinin by captopril in rats[J]. J Cardiovasc harmacol,2004,43: 685-691.
[9]许昌声,翁智远,王华军,等.SHR,WKY大鼠心,肾及胸主动脉ACE, ACE2表达的差异与高血压的关系.中国比较医学杂志,2006,7(16)：402-407.
[10]林杰,田海红,秦旭平,等.氯沙坦对肾性高血压大鼠血管中ACE2 mRNA和蛋白质表达水平的影响.中南药学,2010,1(8)：6-10.
[11]Bernard I, Levy. How to Explain the Differences Between Renin Angiotensin System Modulators [J]. American Journal of Hypertension,2005,18(9):134-141.
[12]Sravros Apostolakis, Elias Krambovitis, Zaharenia Vltats, et al. CX3CR1 receptor is up-regulated in monocytes of coronary artery diseased patients:Impact of pre-inflammatory stimuli and rennin angiotensin system modultors [J]. Thrombosis Research,2007,121(3):387-395.